The Prostate and Urologic Cancer Research Group conducts and supports research on prostate and bladder cancers, and new approaches to clinical prevention studies including cancer immunoprevention. The group develops, implements and monitors research efforts in chemoprevention, nutrition, genetic, and immunologic interventions, screening, early detection and other prevention strategies.
Phase 0/I/II Cancer Prevention Clinical Trials Program
The group jointly administers the Phase 0/I/II Cancer Prevention Clinical Trials Program evaluating new agents, surrogate biomarkers, and technologies to identify premalignant lesions, and related cancers.
PREVENT Cancer Preclinical Drug Development Program
The group works closely with the PREVENT program, housed in the Chemopreventive Agent Development Research Group, on developing new animal models for ovarian cancer that can be used to evaluate chemopreventive agents, as well as developing new agents for breast and gynecologic cancers.